Advisory
Commission on Childhood Vaccines Meeting
(Conference Call)
June
7, 2007
Minutes
Members Present
- Jeffrey
M. Sconyers, J.D, Chair
-
Marguerite E. Willner, Vice-Chair
- Tawny
Buck
-
Jaime Deville, M.D.
-
William P. Glass, Jr., J.D.
-
Tamara Tempfer, RN-C, MSN, PNP
-
Loren Cooper, J.D.
Ex-Officio
Members Present
-
John Iskander, M.D., M.P.H., Associate
Director, Immunization Safety Office,
Office of the Chief Science Officer,
Centers for Disease Control and Prevention
-
Barbara Mulach, Ph.D., for Carole Heilman,
Ph.D./National Institute of Allergy
and Infectious Diseases
(NIAID), National Institutes of Health
(NIH)
Executive Secretary
- Geoffrey Evans, M.D., Director, Division
of Vaccine Injury Compensation (DVIC),
Healthcare Systems Bureau (HSB), Health
Resources and Services Administration
(HRSA)
Staff
Liaison
- Cheryl
Lee, DVIC, HSB, HRSA
Introduction
Mr.
Sconyers convened the 66th quarterly meeting
of the Advisory Commission of Childhood
Vaccines (ACCV) at 1:10 p.m., via teleconference,
and welcomed all participants. The minutes
of the March 7-8, 2007 meeting were unanimously
approved.
Report
from the Division of Vaccine Injury Compensation
(DVIC): Geoffrey Evans, M.D., Director
ACCV
Membership
Dr.
Evans expressed appreciation to the retiring
ACCV members -- Marguerite WiIlner, Loren
Cooper, J.D. and Don Wilber, M.D. for
their dedicated service to the ACCV. After
reviewing the agenda, he announced three
new members. Margaret Fisher, M.D., FAAP,
is replacing Dr. Don Wilber in
the category of physician with expertise
in pediatric medicine. She is the Medical
Director of Children's Hospital at Monmouth
Medical Center and Professor of Pediatrics
at Drexel University College of Medicine.
She is a member of the American Academy
of Pediatrics Committee on Infectious
Diseases, otherwise known as the Red Book
Committee. Charlene Gallagher, J.D. is
replacing Loren Cooper in the
category of attorney representing the
vaccine industry. She is Division Counsel
of the Vaccines Business Unit at Wyeth
Pharmaceuticals, and is responsible for
clinical trial matters, and the review
and approval of promotional materials
and labeling documents. She was previously
a pharmaceutical chemist, and has served
as chair of the Pharmaceutical Research
and Manufacturers of America’s Product
Liability Committee, and taught food and
drug law as an adjunct professor at Temple
University. Finally, Ms. Magdalena Castro
Lewis is replacing Marguerite Willner
in the category of general public
member. She is the Director of the Center
for Providers at the National Alliance
for Hispanic Health. She directed the
“Vaccines for the Family”
Project and “Vaccines for the Time
of Birth” Program and other initiatives.
In addition, she planned and managed the
National Hispanic Immunization Hotline
and the National Hispanic Prenatal Hotline
for the Alliance. Finally, Dr. Evans noted
that Robin Stavola, who is a parent of
a vaccine-injured child, had resigned
from the ACCV because of personal and
professional commitments.
Statistical
Report
Dr.
Evans stated that the number of autism
claims filed continued to decline. As
of April 30, only 70 had been filed this
fiscal year (FY). The number of non-autism
claims filed is 109, and will probably
increase because of the upcoming 2-year
deadline on July 1 for influenza vaccines
that ends the 8-year retroactive coverage
filing period whenever a new vaccine is
added to the Vaccine Injury Table. Annual
awards have been fairly consistent for
the past several years, averaging around
$58 million for petitioners and $4 million
for legal fees. The FY 2007 awards are
down slightly at $43.6 million to date.
The Vaccine Injury Compensation Trust
Fund balance is $2.5 billion and increasing
at a higher rate than before because of
the addition of influenza vaccine. About
$300 million will be added in 2007, one-third
of which derives from interest on the
principal.
Awards
On
April 24, the largest single award since
the inception of the National Vaccine
Injury Compensation Program (VICP) was
made, a $10 million award consisting of
three annuity contracts and four lump
sums. It was awarded to Mario Arturo Rodriguez
for a measles, mumps, and rubella vaccine-related
injury. This case received national media
attention.
DVIC
Activities
Dr.
Indira Jevaji, represented the VICP as
an ex officio member of the Advisory Committee
on Immunization Practices meeting on February
20-22 in Atlanta. Dr. Jevaji also attended
the Vaccines and Related Biological Products
Advisory Committee (VRBPAC) Meeting on
February 27. The first licensed U.S. vaccine
to protect against the H5N1 avian flu
virus was approved by the Food and Drug
Administration on April 17. This vaccine
will be part of the Federal government’s
vaccine stockpile.
DVIC
staff and Marguerite Willner, representing
the ACCV, attended the Post-Marketing
Surveillance Meeting at NIH on April 10-11.
The purpose of this meeting was to discuss
what an ideal post-licensure vaccine system
would be.
From
April 24-27, Dr. Evans attended back to
back meetings of the Clinical Immunization
Safety Assessment (CISA) Network and the
Vaccine Safety Datalink project in Atlanta.
Both are CDC-sponsored efforts. CISA,
which utilizes seven academic centers
across the county, conducts focused research
on individuals who experience serious
adverse events after vaccination. The
VSD is CDC’s primary post-marketing
surveillance tool used to monitor vaccine
safety by conducting research on linked
databases from eight Medical Care Organizations.
On
May 10-11, Dr. Evans and ACCV Vice Chair,
Jaime Deville, M.D. participated in the
CDC’s Immunization Safety Office
(ISO) Scientific Consultancy, providing
comments to the ISO on its efforts to
develop a new vaccine safety research
agenda. CDC plans to share results of
this and other sessions with the National
Vaccine Advisory Committee as part of
a new effort to engage the public in setting
priorities for safety research.
Finally,
Dr. Jevaji attended the VRBPAC meeting
on May 16. A biologics license application
was under consideration from MedImmune
for Flumist (the live, attentuated, intranasal
influenza vaccine [LAIV]). The company
is requesting an expanded indication for
active immunization of healthy individuals
from 5-49 years of age down to age 1.
The Committee also considered which strains
of flu should be included in the trivalent
vaccine for the 2007-2008 flu season.
In
terms of Congressional activity, Dr. Evans
had nothing new to report since the last
meeting.
Discussion
Ms.
Willner requested a briefing for the ACCV
on the criteria for selecting ACCV members.
She suggested that it would be appropriate
to recruit new ACCV members who had been
active participants in the VICP, perhaps
an individual who had been involved in
an extended causation case, or an attorney
who had handled a large number of cases.
Dr. Evans agreed that a briefing would
be appropriate, adding that it has been
a challenge to obtain a list of candidates
with such experience and even a greater
challenge to obtain a commitment by such
an experienced individual to serve.
Ms.
Buck requested that, at future meetings,
the financial information on awards be
expanded to include the expenditures on
the Federal government for attorney’s
fees, expert witness fees, etc. Mr. Mark
Rogers, Deputy Director, Torts Branch,
Civil Division, Department of Justice
explained that there is a $6 million annual
budget and a detail of the expenditures
can be presented in the DOJ report at
the next meeting.
Report
from the Department of Justice: Mark Rogers,
J.D, Deputy Director, Torts Branch, Civil
Division,
Mr.
Rogers welcomed the three incoming ACCV
members and expressed the Department’s
appreciation to the outgoing Commission
members.
Staffing
and Hiring
Administratively,
the Office of Vaccine Litigation, Department
of Justice (DOJ), has 15 trial attorneys
on staff, and has extended an offer to
another attorney who will be joining DOJ
in 2007. DOJ plans to hire one more attorney,
for a total of 17 trial attorneys, to
process cases. Mr. Rogers expected an
increase in staffing to assist processing
influenza and autism vaccine claims.
Litigation
In
the three months since the last ACCV meeting,
46 non-autism and 18 autism petitions
were filed. Mr. Rogers predicted that
180 non-autism petitions would be filed
annually, which is a slight increase from
the last report. Mr. Rogers reminded the
Commission thatthe statute of repose in
the flu cases expires on July 1, 2007,
and that based on DOJ’s experience,
a significant number of flu petitions
would be filed on the last possible day.
Mr. Rogers could not anticipate a number,
but expressed that he would be surprised
if less than fifty or more than three
hundred petitions are filed.
Data
for the last three months reflected that
forty-five non-autism claims were resolved.
Twenty-one of those were compensated;
of those, fifteen were settled. Mr. Rogers
emphasized that DOJ’s practice is
to try and resolve claims through settlement,
which is a win-win situation. From DOJ’s
view, settlement affords the best possible
outcome.
There
were six entitlement decisions that went
against the government, five of those
went to trial and one was a death case
concession by the Department of Health
and Human Services (HHS).
Twenty-four
cases were dismissed, all of which were
non-autism. One petition was withdrawn
pursuant to 42 U.S.C. 300aa-21(b), which
affords petitioners the right to leave
the Program if they do not receive a decision
within a certain timeframe.
There
were 32 entitlement decisions for the
government; three of those followed some
type of a hearing, twelve followed a summary
judgment-type of motion. Summary judgment-type
motions were typically filed in cases
where petitioners requested a decision
on the existing record because they could
not find an expert to support their claim
or they wanted the claim decided based
upon the existing record. Two additional
claims were dismissed for statute of limitations
reasons. Using that data, and extrapolating
for an annual rate, approximately 180
non-autism claims are filed annually.
Thus, as many claims were filed as were
disposed over the course of the last three
months.
Mr.
Rogers reminded the Commission that the
upcoming flu deadline, as well as autism
proceedings, continue to be two factors
on the horizon that may affect case processing.
Appeals
The
appellate practice remains fairly active.
The petition for writ of certiorari to
the United States Supreme Court filed
by petitioners in Pafford v. HHS
that Mr. Rogers mentioned at the last
meeting was denied. A petition for writ
of certiorari to the United States Supreme
Court was filed in the case Markovich
v. HHS. The Markovich case
involves interpretation of the Vaccine
Act’s three year statute of limitations.
As discussed at the last meeting, the
Federal Circuit issued a published decision
affirming the Special Master’s dismissal
of the petition. The key issue is when
the three-year (or 36 month) limitations
period starts to run under the Vaccine
Act. Briefing in the Markovich
case has not started.
At
the Federal Circuit, one case was decided
and a new case was filed. The new case,
which was discussed as part of the Court
of Federal Claims report at the last meeting,
is Avera v. HHS, and involves
the manner and rate of computing payment
of attorneys’ fees and costs. In
that case, the Court of Federal Claims
agreed with the Special Master’s
denial of interim payment of attorneys’fees
and costs, so that issue was also appealed
to the Federal Circuit. Pending before
the Federal Circuit is Zatuchni/Snyder
v. HHS, which was discussed in prior
ACCV meetings. The appeal was filed by
the government, and involves the parameters
of a special master’s authority
to award attorneys’ fees. The issue
below involved an award of death benefits
available under the Act, and briefing
has been completed before the Federal
Circuit.
Since
the last meeting, the case of Walther
v. HHS was decided against the government
by the Federal Circuit. The court held
that the Special Master applied an incorrect
legal standard in accounting for multiple
possible causes of the injury where one
of the possible causes was the vaccine.
The issue involved how the Special Master
addressed the burden of proving or accounting
for those other possible causes forming
the basis for the reversal. That case
will be returned to the Special Master
for processing consistent with the Federal
Circuit’s decision.
At
the Court of Federal Claims level, Mr.
Rogers reported that there are ten cases
pending; five are new from the last meeting.
Of those new five, four were filed by
petitioners and one by the government.
Since the last meeting, four cases were
decided by the Court of Federal Claims.
The case Hocraffer v. HHS, filed
by petitioner, involves whether the Special
Master erred by excluding some of petitioner’s
additional evidence offered during the
damages phase regarding the entitlement
question. Petitioner also argues that
the Special Master abused his discretion
in calculating the pain and suffering
award. In the case McGrath v. HHS,
petitioner appealed and argues that the
Special Master applied an incorrect billing
rate for attorneys’ fees. In the
case Ruiz v. HHS, filed by petitioner,
the issue is whether the Special Master
properly dismissed the petition for failure
to establish that residual effects of
the alleged vaccine-related injury lasted
for more than six months a requirement
under the Program for receiving compensation.
In the case Moberly v. HHS, petitioner
appealed, and argues that the Special
Master erred by failing to consider the
record as a whole and imposed too great
a burden of proof on petitioner by requiring
conclusive scientific literature to support
the claim. In essence, the petitioner
in Moberly has argued that the
Special Master violated the Federal Circuit’s
decision in Althen v. HHS.
Autism
Mr.
Rogers offered an update on the impending
autism hearing. He reminded the committee
that there are approximately 4,750 claims
pending in the Omnibus Autism Proceeding.
The first evidentiary hearing is scheduled
for June 11, in the first test case, Cedillo
v. HHS. Reiterating his points from
the last meeting, Mr. Rogers noted that
the Office of Special Masters had decided
to hear evidence on petitioner’s
first theory of causation using three
test cases. They appointed two additional
special masters to hear these cases. Special
Master Campbell-Smith and Special Master
Vowell. The second designated test case
is Hazelhurst v. HHS. The tentative
trial schedule for that case is mid-October.
Petitioners have not yet designated a
third test case. Administratively, Mr.
Rogers explained that the Cedillo
hearing will be held at the Court of Federal
Claims, from 9:00 a.m. 6:00 p.m., daily.
The Court will open at 7:30 a.m. The hearing
is expected to last approximately three
weeks and is open to the public. There
are two options for following the proceedings.
There will be a daily transcript generated
of the testimony that will be available
on the Court of Federal Claims’s
website, as well as telephonic access
using a code that is available through
the Court’s website.
Mr.
Rogers concluded his presentation and
several questions followed.
Questions
Ms.
Marguerite Willner advised that a Futures
Workgroup was convening the following
day. She expressed that she and other
members of the ACCV received complaints
about DOJ attorneys using a small number
of settlement brokers to purchase annuities.
Ms. Willner questioned the use of brokers
by the DOJ. Mr. Rogers responded by noting
that the settlement broker works for the
party who places the annuity. In this
case, the annuity is purchased by the
government, thus the broker works for
the government. Mr. Rogers further explained
that in such a scenario, the parties do
not jointly purchase a government annuity,
the settlement broker works exclusively
for HHS, the purchaser of the annuity.
Noting that such concerns have been raised
in the past, Mr. Rogers emphasized that
a petitioner can hire a financial advisor
to obtain financial advice or planning
regarding how a settlement is to be structured.
Such financial advice can be billed to
the Program at the conclusion of the case
as a cost under the fee-shifting statute
of the Act.
Ms.
Willner questioned whether or not reimbursement
of such services for persons, whom she
identified as settlement advisors or brokers,
had been compensated under the Act previously.
Mr. Rogers clarified the use of the term
broker stating that one party hires a
broker to purchase the government owned
annuity. That is not a joint activity.
Offering to explain the process briefly,
Mr. Rogers explained two parts to the
process.
First, one develops what the stream of
payments should be, which is done customarily
by a settlement broker that is expected
to be hired by the government for the
purpose of placing an annuity. Petitioner’s
concern is not the cost of the annuity;
rather, it is the amount of the payments
and when will they be received. Conceptually,
a petitioner may need the services of
nurse practitioners, health professionals,
or others to advise petitioner in those
matters. The terms of payment are reduced
to a decision issued by a special master.
At that point, an annuity broker is needed
to purchase the annuity on behalf of the
government. Petitioner’s interest
is protected in setting the criteria for
the annuity company from which an annuity
is purchased. Once judgment issues in
a case, the remaining issue is which annuity
company to use according to the standards
set by the special master. The selection
of the company is between HHS and the
life insurance company, not petitioner.
Ms.
Willner questioned the percentage paid
to the broker who places the annuity,
which was deferred to the Futures Workgroup.
Dr. Evans advised that DOJ attorney Melonie
McCall was expected to speak on this topic
at tomorrow’s workgroup meeting.
Mr. Rogers concluded his remarks on this
subject in response to Ms. Buck’s
follow-up question on how brokers are
selected by offering that, as a matter
of policy, the government welcomes any
brokers to participate in the process.
The recurring question for DOJ in using
brokers is whether or not the broker is
experienced and qualified.
Petitioners’
Attorney Report on Autism Proceeding:
Thomas Powers, J.D.
Mr.
Powers reported that the first autism
case, Cedillo v. HHS, will begin
June 11, and is scheduled to last about
three weeks. The petitioner will call
six expert witnesses and a family representative,
and that testimony should take about a
week. The DOJ has submitted a list of
13 experts. The petitioner’s claim
is based on a theory that the interaction
between thimerosal-containing vaccines
and the measles-mumps-rubella (MMR) vaccine
suppresses the immune system in a small
number of children, making them vulnerable
to a viral infection that results in neurological
injury, often manifested as autism.
The
second autism test case is designated,
and Curtis Webb is the petitioner’s
attorney for this case. A third case will
be designated later, probably by August.
All three cases will be based on the same
theory. Each case will be heard by a different
special master who will write the final
opinion, although all three will be present
in the three cases. All opinions should
be issued by early 2008.
Mr.
Powers explained that there is a second
theory of causation, that the form of
mercury in thimerosal has a direct neurotoxic
effect that causes injury, including injury
that may result in autism. The three test
case petitioners applying under the first
theory are also submitting medical records
to support a claim under the second theory.
In
addition to the webcast and the transcript
available on the web, a downloadable audio
file of each hearing day will be made
available. All require individual password
registration. Based on the outcomes of
the three test cases, the objective of
the special masters is to develop guidance
through their decisions to apply to individual
cases with similar facts to the test cases.
Although future petitioners may choose
to pursue an independent claim, it is
hoped that the test cases and the resulting
guidelines will result in a workable and
meaningful criteria that will obviate
the need for individual claims.
Asked
about a timeline for the process, Mr.
Powers stated that Special Master Hastings
is committed to an expeditious process,
but there will be three decisions and
there may be appellate issues.
Report
on the CDC Immunization Safety Office
Consultancy Meeting and the ACCV Futures
II Work Group: Jaime Deville, M.D.
Dr.
Deville reported on the CDC’s Immunization
Safety Office (ISO) Consultancy meeting
in May that he attended. At the meeting,
the activities of the ISO – the
Vaccine Adverse Event Reporting System,
the Vaccine Safety Datalink, the Clinical
Immunization Safety Assessment Network,
and the Brighton Collaboration –
all of which have different, but complementary
missions, were discussed. One presentation
covered the history of vaccine safety
monitoring and highlighted the importance
of detection and rapid assessment of rare
events, which is germane to the current
autism issue. The speaker pointed out
the importance of assessing the costs
of these rare events and the timely development
of contraindications for the vaccines.
Finally, he discussed the appearance of
chronic diseases which may occur years
after vaccinations.
Dr.
Deville stated that the ACCV Futures II
Workgroup is currently discussing identifying
stable sources of funding for future vaccine
safety research. One possibility using
a portion of the substantial Vaccine Injury
Compensation Trust Fund, to allow some
fraction of future incoming revenues to
be diverted to research which might be
accomplished by tapping part of interest
income. This would require legislative
changes to the VICP. There was also discussion
about non-Federal sources of funding that
might be used for research.
Secondly,
the Workgroup discussed obtaining information
about underserved populations accessing
the VICP. Many of these populations may
not be aware of the VICP because of language
or cultural barriers. The Workgroup intends
to develop an OMB-approved survey to gather
data on this issue.
Finally,
the structured settlement and the development
of life care plans will be discussed at
the June 8 meeting, and the Chief Special
Master will discuss the delays that affect
the processing of claims.
Ms.
Buck asked about several outreach issues
discussed at the last ACCV meeting –
1) whether a list was available of outside
organization meetings at which DVIC representatives
participated; 2) whether vaccine safety
materials could be distributed through
various associations or other non-Federal
organizations; and 3) whether DVIC could
develop a collaboration with the Association
of Immunization Managers (AIM). Dr. Evans
stated that the first two were action
items that would be addressed before the
next meeting, and he would look into a
possible collaboration with AIM. He reminded
members that DVIC stopped exhibiting at
meetings several years ago when HRSA decided
to centralize all program outreach activities.
DOJ has continued their outreach efforts
by attending several legal or medical
professional meetings annually.
There
was a brief discussion about both the
HRSA and DOJ budgets as they affect DVIC
and ACCV funding. Dr. Evans and Mr. Rogers
agreed to discuss budget issues at the
Workgroup meeting.
Update
on the ISO: John Iskander, M.D., M.P.H.,
Associate Director for Science, ISO, CDC
Rotateq
and Intussusception
Dr.
Iskander reviewed recent developments
related to the incidence of intussusception
following Rotateq, an oral retrovirus
vaccine. The CDC post-marketing surveillance
has indicated that Rotateq is not associated
with intussusception (as of February 15)
and the CDC has reaffirmed its policy
recommendation for vaccination of infants
at 2, 4 and 6 months of age. There were
35 VAERS adverse event reports, half within
21 days of administration, the remainder
out to 33 days, and there was no apparent
“clustering,” multiple events
occurring at a specific time after administration.
The Vaccine Safety Datalink indicates
that the background rate for intussusception
within three weeks of administration should
be 52 cases, which suggests that the rate
was not excessive. In a 1-year period
starting on February 1, 2006, about 28,000
doses of Rotateq were administered to
infants in VSD-monitored HMOs, and there
were no cases of intussusception reported
within the first 30 days.
Menactra
and Guillain-Barre Syndrome
Concerning
the vaccine Menactra, Dr. Iskander reported
that the incidence of Guillain-Barre Syndrome
(GBS) after Menactra vaccination appears
to be slightly higher in children in the
older age range of 15 to 19 years of age.
However, this is soft data because there
is probably underreporting in VAERS. Because
of the potential serious risk of GBS,
even though it is rare (about one in a
million vaccinations), a larger study
will be conducted by Harvard Pilgrim Health
Care over a period of two years. The study
will be funded by industry, although an
oversight group that will include Federal
representation will be formed to monitor
the study. Ms. Buck asked for additional
information on how the oversight group
would be constituted and Dr. Iskander
said that he would provide this information.
Pertussis
Vaccines
Dr.
Iskander reported on data presented at
the ACIP meeting on adult and adolescent
pertussis vaccines (Tdap). A summary of
VAERS reports indicated some minor adverse
effects temporal proximity with vaccination,
most of which were anticipated. There
were a few deaths during the reporting
period, but none appeared to be related
to the vaccine. There were also a few
GBS incidents, but the probable cause
was confounded because multiple vaccines
were involved (which often included Menactra).
Future
Events
Dr.
Iskander listed several topics to be discussed
at the next Advisory Committee on Immunization
Practices (ACIP) meeting on June 27-28.
These include: safety and immunogenicity
of Pentacel, vaccines during pregnancy
and breastfeeding, an update on FluMist
safety monitoring, and updates on Rotateq
and human papillomavirus (HPV) vaccine.
Regarding
the development of a research agenda for
the ISO, the Scientific Consultancy meeting
was held on May 10-11 and Drs. Evans and
Deville attended the meeting. Now, the
ISO will seek input from a variety of
partners. On June 7, ISO staff are presenting
to the Safety Subcommittee of the National
Vaccine Advisory Committee and will be
presenting to the CDC Vaccine Interest
Group, the Interagency Vaccine Group and
the ACIP later. The Global Advisory Committee
of Vaccine Safety will meet in Geneva
and ISO will present data on GBS and Menactra,
Rotateq and HPV vaccine. Finally, on May
23, Judicial Watch reported three deaths
following HPV vaccine, none of which appeared
to be directly related to the vaccine.
Asked
about mix-ups in administering pediatric
versus adult/adolescent pertussis vaccines,
Dr. Iskander noted that there had been
such errors, but there had been no significant
reports of adverse medical outcomes.
Update
on National Institute of Allergy and Infectious
Diseases (NIAID) Vaccine Activities: Barbara
Mulach, Ph.D., NIAID, NIH
Dr.
Mulach reported on NIAID vaccine activities
focusing on early-stage research and evaluation
of new vaccines. Currently, clinical studies
are looking at various clades of avian
flu vaccines, including the most effective
use of these vaccines and the recently
licensed H5N1 avian flu vaccine, the effect
of adjuvants on efficacy, and how different
routes of administration may affect efficacy.
Six Centers of Excellence have been funded
to conduct research and surveillance on
animals to complement work being done
in the human population. Finally, the
NIAID tuberculosis (TB) working group,
along with the larger TB community, has
been developing a research strategy for
addressing drug-resistant TB.
Dr.
Mulach noted that the Jordan
Report (Adobe/PDF) is now available
at the NIAID
Website, which includes an update
on vaccine development for certain diseases.
Future Agenda Items
Mr.
Sconyers stated that there would be a
report on the ACCV Futures II Workgroup
activities at the next meeting. He added
that, in the future, ACCV members would
be invited to submit agenda topics by
e-mail at any time.
There
was a suggestion that the process of ACCV
member selection be explained in detail
at the next meeting, including specific
numbers if available. Ms. Buck requested
that there be a report on the honoraria
issue, and also asked for a discussion
of the decision process that leads to
conceding cases.
Adjournment
Dr.
Evans announced that Delia Jones would
be leaving DVIC before the next meeting.
He expressed appreciation for her dedication
and service.
The
meeting adjourned at 3:10 p.m.
__________________________
Jeffrey Sconyers, J.D.
ACCV Chair |
________________________
Marguerite Willner
ACCV Vice-Chair
|
__________________________
Geoffrey Evans, M.D.
Executive Secretary, ACCV |
__________________________
Date |
This
information reflects the current thinking of the United States Department
of Health and Human Services on the topics addressed. This information is
not legal advice and does not create or confer any rights for or on any
person and does not operate to bind the Department or the public. The ultimate
decision about the scope of the statutes authorizing the VICP is within
the authority of the United States Court of Federal Claims, which is responsible
for resolving claims for compensation under the VICP.
|
|